Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bilgin

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Blood Advances|August 22, 2025
Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trialFebe Smits, Kaz Groen, Mark-David Levin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 StudyClaudia A M Stege, Kazem Nasserinejad, Ellen van der Spek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin LymphomaSuzanne I M Neppelenbroek, Yvonne M Geurts, Berthe M P Aleman, et al.
Haematologica|December 1, 2020
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, et al.
Hemasphere|October 31, 2022
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA ReportJon Salmanton-García, Francesco Marchesi, Andreas Glenthøj, et al.
Blood|November 8, 2021
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHALivio Pagano, Jon Salmanton-García, Francesco Marchesi, et al.
ESMO Open|February 13, 2024
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphomaY M Geurts, S I M Neppelenbroek, B M P Aleman, et al.
Leukemia|February 16, 2021
Improving the identification of frail elderly newly diagnosed multiple myeloma patientsClaudia A M Stege, Kazem Nasserinejad, Saskia K Klein, et al.
Journal of Hematology & Oncology|April 3, 2023
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registryFrancesco Marchesi, Jon Salmanton-García, Caterina Buquicchio, et al.
Blood Advances|May 2, 2022
COVID-19 and hairy-cell leukemia: an EPICOVIDEHA surveySylvain Lamure, Jon Salmanton-García, Elena Robin-Marieton, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Blood Advances|August 22, 2025
Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trialFebe Smits, Kaz Groen, Mark-David Levin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 StudyClaudia A M Stege, Kazem Nasserinejad, Ellen van der Spek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin LymphomaSuzanne I M Neppelenbroek, Yvonne M Geurts, Berthe M P Aleman, et al.
Haematologica|December 1, 2020
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, et al.
Hemasphere|October 31, 2022
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA ReportJon Salmanton-García, Francesco Marchesi, Andreas Glenthøj, et al.
Blood|November 8, 2021
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHALivio Pagano, Jon Salmanton-García, Francesco Marchesi, et al.
ESMO Open|February 13, 2024
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphomaY M Geurts, S I M Neppelenbroek, B M P Aleman, et al.
Leukemia|February 16, 2021
Improving the identification of frail elderly newly diagnosed multiple myeloma patientsClaudia A M Stege, Kazem Nasserinejad, Saskia K Klein, et al.
Journal of Hematology & Oncology|April 3, 2023
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registryFrancesco Marchesi, Jon Salmanton-García, Caterina Buquicchio, et al.
Blood Advances|May 2, 2022
COVID-19 and hairy-cell leukemia: an EPICOVIDEHA surveySylvain Lamure, Jon Salmanton-García, Elena Robin-Marieton, et al.
Pageof 8